Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
Intervalo de año de publicación
1.
Small ; : e2404019, 2024 Jul 24.
Artículo en Inglés | MEDLINE | ID: mdl-39045905

RESUMEN

Developing electrocatalysts with excellent activity and stability for water splitting in acidic media remains a formidable challenge due to the sluggish kinetics and severe dissolution. As a solution, a multi-component doped RuO2 prepared through a process of dealloying-annealing is presented. The resulting multi-doped RuO2 possesses a nanoporous structure, ensuring a high utilization efficiency of Ru. Furthermore, the dopants can regulate the electronic structure, causing electron aggregation around unsaturated Ru sites, which mitigates Ru dissolution and significantly enhances the catalytic stability/activity. The representative catalyst (FeCoNiCrTi-RuO2) shows an overpotential of 167 mV at 10 mA cm-2 for oxygen evolution reaction (OER) in 0.5 m H2SO4 solution with a Tafel slope of 53.1 mV dec-1, which is among the highest performance reported. Moreover, it remains stable for over 200 h at a current density of 10 mA cm-2. This work presents a promising approach for improving RuO2-based electrocatalysts, offering a crucial advancement for electrochemical water splitting.

2.
Nanoscale Horiz ; 9(9): 1506-1513, 2024 Aug 19.
Artículo en Inglés | MEDLINE | ID: mdl-38919145

RESUMEN

The design and synthesis of highly durable and active electrocatalysts are crucial for improving the hydrogen evolution reaction (HER) and oxygen reduction reaction (ORR) in proton exchange membrane fuel cells (PEMFCs). In this work, we present a novel dealloyed nanoporous PtCuNiCoMn multicomponent alloy with ligaments/pores ranging from 2-3 nm, which is in situ encapsulated in a three-dimensional, free-standing nanoporous nanotubular graphene network featuring a pore/tube diameter of ∼200 to 300 nm. This method allows precise control over the noble metal loading and alloy composition while preventing noble metal loss throughout the preparation process. The innovative bimodal nanoporous graphene/alloy structure, coupled with an open 3D spongy morphology, and optimized surface Pt electronic structure through multicomponent interaction, significantly enhances the activity for the HER/ORR, outperforming commercial Pt/C. Moreover, this design addresses the issues of Pt nanoparticle aggregation and detachment from carbon supports that typically exist in Pt/C-type catalysts, thereby substantially improving the catalytic durability, even under intense gas bubbling conditions.

3.
ACS Nano ; 18(11): 8531-8545, 2024 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-38456901

RESUMEN

Programmed death-ligand 1 (PD-L1) is a promising target for cancer immunotherapy due to its ability to inhibit T cell activation; however, its expression on various noncancer cells may cause on-target off-tumor toxicity when designing PD-L1-targeting Chimeric Antigen Receptor (CAR) T cell therapies. Combining rational design and directed evolution of the human fibronectin-derived monobody scaffold, "PDbody" was engineered to bind to PD-L1 with a preference for a slightly lower pH, which is typical in the tumor microenvironment. PDbody was further utilized as a CAR to target the PD-L1-expressing triple negative MDA-MB-231 breast cancer cell line. To mitigate on-target off-tumor toxicity associated with targeting PD-L1, a Cluster of Differentiation 19 (CD19)-recognizing SynNotch IF THEN gate was integrated into the system. This CD19-SynNotch PDbody-CAR system was then expressed in primary human T cells to target CD19-expressing MDA-MB-231 cancer cells. These CD19-SynNotch PDbody-CAR T cells demonstrated both specificity and efficacy in vitro, accurately eradicating cancer targets in cytotoxicity assays. Moreover, in an in vivo bilateral murine tumor model, they exhibited the capability to effectively restrain tumor growth. Overall, CD19-SynNotch PDbody-CAR T cells represent a distinct development over previously published designs due to their increased efficacy, proliferative capability, and mitigation of off-tumor toxicity for solid tumor treatment.


Asunto(s)
Antígeno B7-H1 , Receptores de Antígenos de Linfocitos T , Humanos , Ratones , Animales , Receptores de Antígenos de Linfocitos T/metabolismo , Antígeno B7-H1/genética , Antígeno B7-H1/metabolismo , Ligandos , Línea Celular Tumoral , Linfocitos T , Inmunoterapia Adoptiva
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA